Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elio Adib

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
JAMA Oncology|November 17, 2022
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLCMehrdad Rakaee, Elio Adib, Biagio Ricciuti, et al.
Cell Reports|February 14, 2026
Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritabilitySarah Abou Alaiwi, Elio Adib, Ziwei Zhang, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Science Advances|November 22, 2023
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou, Judit Börcsök, Elio Adib, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Journal of the National Cancer Institute|December 19, 2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancerAmin H Nassar, Elias Bou Farhat, Hassan Abushukair, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-AnalysisLeonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 27, 2024
Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
JTO Clinical and Research Reports|March 19, 2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective StudyElio Adib, Amin H Nassar, Katie N Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 7, 2024
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United StatesKathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
JAMA Oncology|November 17, 2022
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLCMehrdad Rakaee, Elio Adib, Biagio Ricciuti, et al.
Cell Reports|February 14, 2026
Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritabilitySarah Abou Alaiwi, Elio Adib, Ziwei Zhang, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Science Advances|November 22, 2023
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou, Judit Börcsök, Elio Adib, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Journal of the National Cancer Institute|December 19, 2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancerAmin H Nassar, Elias Bou Farhat, Hassan Abushukair, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-AnalysisLeonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 27, 2024
Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
JTO Clinical and Research Reports|March 19, 2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective StudyElio Adib, Amin H Nassar, Katie N Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 7, 2024
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United StatesKathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
Pageof 5